Tempest Therapeutics, Inc. cotiza a 0.74 USD y tiene una capitalización bursátil de $13M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metasta…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.50 | $-0.62 |
| Estimado | $-0.35 | $-0.30 | $-0.28 | $-0.62 |
| Sorpresa | — | — | -78.6% | +0.0% |
| Métrica | TPST | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -393.9% | -40.4% | -353.5% |
| ROA | -155.1% | -32.0% | -123.1% |
| Current Ratio | 2.50 | 2.84 | -0.34 |
| Debt / Equity | — | 0.28 | — |